| Effects of pay for performance in health care: a systematic review of systematic reviews F Eijkenaar, M Emmert, M Scheppach, O Schöffski Health policy 110 (2-3), 115-130, 2013 | 701 | 2013 |
| Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project PL Kolominsky-Rabas, PU Heuschmann, D Marschall, M Emmert, ... Stroke 37 (5), 1179-1183, 2006 | 617 | 2006 |
| Grundformen gesundheitsökonomischer Evaluationen O Schöffski Gesundheitsökonomische Evaluationen: Dritte, vollständig öberarbeitete …, 2007 | 471* | 2007 |
| Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease S Merkesdal, J Ruof, O Schöffski, K Bernitt, H Zeidler, W Mau Arthritis & Rheumatism 44 (3), 528-534, 2001 | 174 | 2001 |
| Economic evaluation of pay-for-performance in health care: a systematic review M Emmert, F Eijkenaar, H Kemter, AS Esslinger, O Schöffski The European Journal of Health Economics 13, 755-767, 2012 | 171 | 2012 |
| German recommendations on health economic evaluation: third and updated version of the Hanover Consensus JM Graf von der Schulenburg, W Greiner, F Jost, N Klusen, M Kubin, ... Value in health 11 (4), 539-544, 2008 | 158 | 2008 |
| Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults HM Hamer, R Dodel, A Strzelczyk, M Balzer-Geldsetzer, JP Reese, ... Journal of neurology 259, 2376-2384, 2012 | 155 | 2012 |
| Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study S Sohn, O Schöffski, J Prinz, K Reich, E Schubert, K Waldorf, M Augustin Dermatology 212 (2), 137-144, 2006 | 141 | 2006 |
| Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation-dritte und aktualisierte Fassung des Hannoveraner Konsens JMG von der Schulenburg, W Greiner, F Jost, N Klusen, M Kubin, R Leidl, ... Gesundheitsökonomie & Qualitätsmanagement 12 (05), 285-290, 2007 | 137 | 2007 |
| Costs and quality of life in patients with moderate to severe plaque‐type psoriasis in Germany: A multi‐center study O Schöffski, M Augustin, J Prinz, K Rauner, E Schubert, S Sohn, K Reich JDDG: Journal der Deutschen Dermatologischen Gesellschaft 5 (3), 209-218, 2007 | 122 | 2007 |
| Resource utilization and costs of stroke unit care in Germany RC Dodel, C Haacke, K Zamzow, S Pawelzik, A Spottke, M Rethfeldt, ... Value in Health 7 (2), 144-152, 2004 | 118 | 2004 |
| Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper L Breitscheidel, S Stamenitis, FW Dippel, O Schöffski Journal of medical economics 13 (1), 8-15, 2010 | 109 | 2010 |
| Public reporting in Germany: the content of physician rating websites M Emmert, U Sander, AS Esslinger, M Maryschok, O Schöffski Methods of information in medicine 51 (02), 112-120, 2012 | 99 | 2012 |
| Adverse drug events in patients admitted to an emergency department: an analysis of direct costs F Meier, R Maas, A Sonst, A Patapovas, F Müller, B Plank‐Kiegele, ... Pharmacoepidemiology and drug safety 24 (2), 176-186, 2015 | 97 | 2015 |
| Grundprinzipien einer Wirtschaftlichkeitsuntersuchung W Greiner, O Schöffski Gesundheitsökonomische Evaluationen: Dritte, vollständig öberarbeitete …, 2007 | 81* | 2007 |
| Betriebliches Gesundheitsmanagement: mit gesunden Mitarbeitern zu unternehmerischem Erfolg AS Esslinger, M Emmert, O Schöffski Springer-Verlag, 2010 | 76* | 2010 |
| Costs of acute stroke care on regular neurological wards: a comparison with stroke unit setting Y Epifanov, R Dodel, C Haacke, M Schaeg, O Schöffski, M Hennerici, ... Health Policy 81 (2-3), 339-349, 2007 | 76 | 2007 |
| Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. S Merkesdal, J Ruof, JL Huelsemann, O Schoeffski, A Maetzel, W Mau, ... The Journal of rheumatology 28 (3), 657-661, 2001 | 75 | 2001 |
| Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013—a ten-year overview LM Willems, S Richter, N Watermann, S Bauer, KM Klein, JP Reese, ... Epilepsy & Behavior 83, 28-35, 2018 | 68 | 2018 |
| What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? S Schneeweiss, O Schöffski, GW Selke Health Policy 44 (3), 253-260, 1998 | 66 | 1998 |
